Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Geminid meteor shower 2025 peaks next week. Here's what you need to know about this year's best meteor shower - 2Raw oysters linked to ongoing salmonella outbreak infecting 64 across 22 states: CDC
- 3Malaysian broadcaster rejects altered graphic about electricity rate hike
- 4Get away from the Tedious Drudgery: Go into Business Today!
- 5They want better health care — so they're turning to crypto startups
- NASA unveils close-up pictures of the comet popping by from another star
- Drones haven't won the fight in Ukraine. That matters as the West learns new ways of war.
- Artemis 2 astronauts reveal adorable zero-g indicator 'Rise' | Space photo of the day for March 31, 2026
- Hezbollah rockets hit 165 UNIFIL positions in Lebanon while targeting Israel, IDF reveals
- What to know about the "wild, wild West" of viral peptide claims
- A definitive Manual for the Over-Ear Earphones
- Wegmans recalls mixed nuts over salmonella contamination fears
- Shelby County deputies charged with assault, placed on leave
- Spanish police and soldiers track boars, reinforce farm security amid swine fever outbreak
